Condition: ER-Positive Breast Cancer · HER2-negative Breast Cancer · Sponsor: The Methodist Hospital Research Institute
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
This description comes directly from the study's public registry record.
Polly Niravath, MD · 713-441-0629 · ccresearch@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05305924